Vascular disease: The tsunami of health care

Stroke

Volumn 38, Issue 12, 2007, Pages 3296-3301

  Hakim, Antoine M ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Dementia; Stroke; Systems change; Vascular disease

Indexed keywords

CANADA; CLINICAL RESEARCH; COGNITIVE DEFECT; CONFERENCE PAPER; HUMAN; HYPERTENSION; PATIENT CARE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; RISK FACTOR; STROKE; VASCULAR DISEASE;

CANADA; DELIVERY OF HEALTH CARE; HEALTH POLICY; HUMANS; HYPERTENSION; PHYSICIAN'S PRACTICE PATTERNS; PREVENTIVE MEDICINE; PRIMARY HEALTH CARE; QUALITY ASSURANCE, HEALTH CARE; RISK FACTORS; VASCULAR DISEASES;

EID: 36448978905     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.107.492793     Document Type: Conference Paper

References (48)

1. Hogan MJ, Hakim AM. Reversibility of nimodipine binding to brain in transient cerebral ischemia. J Neurochem. 1992;59:1745-1752.
2. Hakim AM, Evans AC, Berger L, Kuwabara H, Worsley K, Marchal G, Biel C, Pokrupa R, Diksic M, Meyer E, Gjedde A, Marrett S. The effect of nimodipine on the evolution of human cerebral infarction studied by PET. J Cereb Blood Flow Metab. 1989;523-534.
3. Tissue plasminogen activator for acute ischemic stroke: The rt-PA Stroke Study Group. N Engl J. Med. 1995;333:1581-1588.
4. Matsushima K, Hogan MJ, Hakim AM. Cortical spreading depression protects against subsequent focal cerebral ischemia in rats. J Cereb Blood Flow Metab. 1996;16:221-226.
5. Matsushima K, Schmidt-Kastner R, Hogan MJ, Hakim AM. Cortical spreading depression activates trophic factor expression in neurons and astrocytes and protects against subsequent focal brain ischemia. Brain Res. 1998;807:47-60.
6. Douen AG, Akiyama K, Hogan MJ, Wang F, Dong L, Chow AK, Hakim AM. Preconditioning with cortical spreading depression decreases intraischemic cerebral glutamate levels and down regulates EAAT1 and EAAT2 from rat cerebral cortex plasma membranes. J Neurochem. 2000;75:812-818.
7. Chow AK, Thompson CS, Hogan MJ, Banner D, Sabourin LA, Hakim AM. Cortical spreading depression transiently activates MAP kinases. Molecular Brain Research. 2002;99:75-81.
8. Thompson CS, Hakim AM. Cortical spreading depression modifies components of the inflammatory cascade. Mol Neurobiol. 2005;32:51-57.
9. Gladstone D, Black S, Hakim AM. Toward wisdom from failure: lessons learned from negative stroke treatment trials and new therapeutic frontiers. Stroke. 2002;33:2123-2136.
10. Plautz EJ, Barbay S, Frost SB, Friel KM, Dancause N, Zoubina EV, Stowe AM, Quaney BM, Nudo RJ. Post-infarct cortical plasticity and behavioural recovery using concurrent cortical stimulation and rehabilitative training: a feasibility study in primates. Neurol Res. 2003;25:801-810.
11. Dancause N, Barbay S, Frost SB, Plautz EJ, Chen D, Zoubina EV, Stowe AM, Nudo RJ. Extensive cortical rewiring after brain injury. J Neurosci. 2005;25:10167-10179.
12. Nudo RJ. Mechanisms for recovery of motor function following cortical damage. Curr Opin Neurobiol. 2006;16:638-644.
13. Kolb B, Gibb R. Brain plasticity and recovery from early cortical injury. Dev Psychobiol. 2007;49:107-118.
14. Jadavji NM, Kolb B, Betz GA. Enriched environment improves motor function in intact and unilateral dopamine-depleted rats. Neuroscience. 2006;140:1127-1138.
15. Ukraintseva S, Sloan F, Arbeev K, Yashin A. Increasing rates of dementia at time of declining mortality from stroke. Stroke. 2006;37:1155-1159.
16. Hachinski V. Vascular dementia: a radical redefinition. Dementia. 1994;5:130-132.
17. Hachinski VC. Preventable senility: a call for action against the vascular dementias. Lancet. 1992;340:645-648.
18. Gorelick PB. William M. Feinberg Lecture: Cognitive vitality and the role of stroke and cardiovascular disease risk factors. Stroke. 2005;36:875.
19. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med. 2003;348:1215-1222.
20. Skoog I. Hypertension and cognition. International Psychogeriatrics. 2003;15:139-146.
21. Jauner LJ, Masaki K, Petrovitch H, Foley D, Havlik RJ. The association between midlife blood pressure levels and late-life cognitive function: The Honolulu-Asia Aging Study. JAMA. 1995;274:1846-1851.
22. Leary MC, Saver JF. Annual incidence of first silent stroke in the United States: a preliminary estimate. Cerebrovascular Diseases. 2003;16:280-285.
23. Auero-Torres H, Kivipelto M, Strauss EV. Rethinking the dementia diagnoses in a population-based study: what is Alzheimer's disease and what is vascular dementia? Dement Geriatr Cogn Disord. 2006;22:244-249.
24. Snow KK, Seddon JM. Do age-related macular degeneration and cardiovascular disease share common antecedents?. Ophthalmic Epidemiology. 1999;6:125-143.
25. Tan JS, Mitchell P, Smith W, Wang JJ. Cardiovascular risk factors and the long-term incidence of age-related macular degeneration: The Blue Mountains Eye Study. Ophthalmology. 2007;114:1143-1150.
26. Congdon N, O'Colmain B, Klaver CC, Klein R, Munoz B, Friedman DS, Kempen J, Taylor HR, Mitchell P; Eye Diseases Prevalence Research Group. Causes and prevalence of visual Impairment among adults in the United States. Arch Ophthalmology. 2004;122:477-485.
27. Longstreth WT Jr, Larsen EK, Klein R, Wong TY, Sharrett AR, Lefkowitz D, Manolio TA. Associations between findings on cranial magnetic resonance imaging and retinal photography in the elderly. Am J Epidemiol. 2007;165:78-84.
28. Clemons TE, Rankin MW, McBee WL; Age-related eye disease study research group. Cognitive impairment in the age related eye disease study: AREDS report no. 16. Arch Ophthalmol. 2006;124:537-543.
29. Wong TY, Klein R, Mitchell P, Couper DJ, Lai H, Hubbard LD, Sharrett AR; for the Atherosclerosis Risk in Communities Study. Age-related macular degeneration and risk for stroke. Ann Intern Med. 2006;145:98-106.
30. Neal B, MacMahon S, Chapman N; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet. 2000;356:1955-1964.
31. Estol CJ. The tsunami and stroke; two killer waves. International Journal of Stroke. 2006;1:40.
32. Strong K, Mathers C, Bonita R. Preventing stroke: saving lives around the world. Lancet Neurol. 2007;6:182-187.
33. Ong KL, Cheung BM, Man YB, Lau CP, Lam KS. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension. 2007;49:19-20.
34. Smith EE, Abdullah AR, Amirfarzan H, Schwamm LH. Serum lipid profile on admission for ischemic stroke: failure to meet National Cholesterol Education Program Adult Treatment Panel (NCEP-ATPIII guidelines). Neurology. 2007;68:660-665.
35. Young TK, Hachinski V. The population approach to stroke prevention: a Canadian perspective. Clin Invest Med. 2003;26:78-86.
36. Kannel WB, Dawber TR, Cohen ME, McNamara PM. Vascular Disease of the Brain-Epidemiologic Aspects: The Framingham Study. AM J Public Health Nations Health. 1965;55:1355-1366.
37. Furlan AJ. IV tissue plasminogen activator for stroke in the community: what we know and don't know 10 years after FDA approval. Stroke. 2006;37:281.
38. Kapral MK, Laupacis A, Phillips S, Silver FL, Hill MD, Fang J, Richards JA, Tu JV; for the Investigators of the Registry of the Canadian Stroke Network. Stroke care delivery in institutions participating in the Registry of the Canadian Stroke Network. Stroke. 2004;35:1756-1762.
39. Lewis M, Trypuc J, Lindsay P, O'Callaghan C, Dishaw A. Has Ontario's stroke system really made a difference? Healthc Q. 2006;9:50-59.
40. Bisaillon S, Kelloway L, LeBlanc K, Pageau N, Woloshyn N. Best practices in stroke care. Can Nurse. 2005;101:25-29.
41. Bisaillon S, Douen A, Neabel B, Pageau N, Selchen D. Saving costs using an ounce of prevention: introduction of a regional stroke prevention clinic. Axone. 2006;27:29-33.
42. Campbell NR, Tu K, Brant R, Duong-Hua M, McAlister FA; Canadian Hypertension Education Program Outcomes Research Task Force. The impact of the Canadian hypertension education program on antihypertensive prescribing trends. Hypertension. 2006;47:22-28.
43. Nadeau JO, Shi S, Fang J, Kapral MK, Richards JA, Silver FL, Hill MD; Investigators for the Registry of the Canadian Stroke Network. TPA use for stroke in the Registry of the Canadian Stroke Network. Can J. Neurol Sci. 2006;33:433-439.
44. Alberts MJ, Latchaw RE, Selman WR, Shephard T, Hadley MN, Brass LM, Koroshetz W, Marler JR, Booss J, Zorowitz RD, Croft JB, Magnis E, Mulligan D, Jagoda A, O'Connor R, Cawley CM, Connors JJ, Rose-DeRenzy JA, Emr M, Warren M, Walker MD; Brain Attack Coalition. Recommendations for comprehensive stroke centers: a consensus statement from the Brain Attack Coalition Stroke. 2005;36:1597-1616.
45. Hallenbeck J, Del Zoppo G, Jacobs T, Hakim AM, Goldman S, Utz U, Hasan A; Immunomodulation Workshop Participants. Immunomodulation strategies for preventing vascular disease of the brain and heart: workshop summary. Stroke. 2006;37:3035-3042.
46. Hachinski V, Iadecola C, Petersen RC, Breteler MM, Nyenhuis DL, Black SE, Powers WJ, DeCarli C, Merino JG, Kalaria RN, Vinters HV, Holtzman DM, Rosenberg GA, Wallin A, Dichgans M, Marler JR, Leblanc GG. National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke. 2006;37:2220-2241.
47. Zerhouni EA. Translational research: moving discovery to practice. Clin Pharmacol Ther. 2007;81:126-128.
48. Henderson AJ, Davies J, Willet MR. The experience of Australian project leaders in encouraging practitioners to adopt research evidence in their clinical practice. Aust Health Rev. 2006;30:474-484.